Stem cell engineering induced pluripotent cells

Figure 19.1 Cardiac tissue engineering triad. Schematic representation of the interplay between the components of the cardiac tissue engineering triad. Biomaterials are key components for cardiac tissue engineering applications and play a critical role in this technology. MSC, mesenchymal stem cell ADSC, adipose stem cell iPS, induced pluripotent cell CPC, cardiac progenitor cell VEGF, vascular endothelial growth factor FGF, fibroblast growth factor NRG, neuregulin EPO, erythropoietin HGF, hepatocyte growth factor SDF-1, stromal cell—derived factor 1.

De Peppo, G.M., Marcos-Campos, L, Kahler, D.J., Alsahnan, D., Shang, L., Vunjak-Novakovic, G., Marolt, D., 2013. Engineering bone tissue substitutes from human induced pluripotent stem cells. Proc. Natl. Acad. Sci. USA 110, 8680-8685. 

Montgomery, A., Wong, A., Gabers, N., WiUerth, SM., 2015. Engineering personalized neural tissue by combining induced pluripotent stem cells with fibrin scaffolds. Biomater. Sci. 3 (2), 401-413. 

Cell-based assays typically apply primary cell lines [71], immortalized cell lines [72], engineered cell lines [73], and specific cell types differentiated from induced pluripotent stem cells (iPSC) derived from patients or normal human cells [74]. The throughput of cell-based screening has been greatly improved with advances in new assay technologies, which allows cell-based assays to be miniaturized to allow the rapid screening of large chemical libraries. 

---